Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446505 | 1.00 | PTPN1 (0.44) | PTPN1LMNABLMMEN1CYP3A4 | |
| SCHEMBL23464636 | 0.87 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL1782754 | 0.85 | TSHR (0.36) | PTPN1 | |
| SCHEMBL1782753 | 0.85 | TSHR (0.36) | PTPN1 | |
| SCHEMBL4581846 | 0.83 | PTPN1 (0.47) | PTPN1LMNABLMMEN1CYP3A4 | |
| SCHEMBL4581845 | 0.83 | PTPN1 (0.47) | PTPN1LMNABLMMEN1CYP3A4 | |
| SCHEMBL23414994 | 0.80 | CYP3A4 (0.35) | PTPN1LMNAMEN1CYP3A4ALOX15 | |
| SCHEMBL23414992 | 0.80 | CYP3A4 (0.35) | PTPN1LMNAMEN1CYP3A4ALOX15 | |
| SCHEMBL1785040 | 0.80 | TSHR (0.39) | PTPN1 | |
| SCHEMBL1785043 | 0.80 | TSHR (0.39) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867175-B2 | Trimethyldecenyl compounds | KAO CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1280763-B1 | TRIMETHYLDECENYL COMPOUNDS | KAO CORP (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-20030153485-A1 | Trimethyldecenyl compounds | KAO CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1280763-A1 | TRIMETHYLDECENYL COMPOUNDS | Cognis Deutschland GmbH & Co. KG (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085672-A1 | TRIMETHYLDECENYL COMPOUNDS | COGNIS DEUTSCHLAND GMBH & CO.KG (DE) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153485-A1 | Trimethyldecenyl compounds | CFH, ZYX, XDH | PTPN1 4610/4885LMNA 483/4885BLM 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.